Proton pump inhibitors enhance the effects of cytotoxic agents in chemoresistant epithelial ovarian carcinoma

Oncotarget. 2015 Oct 27;6(33):35040-50. doi: 10.18632/oncotarget.5319.


This study was designed to investigate whether proton pump inhibitors (PPI, V-ATPase blocker) could increase the effect of cytotoxic agents in chemoresistant epithelial ovarian cancer (EOC). Expression of V-ATPase protein was evaluated in patients with EOC using immunohistochemistry, and patient survival was compared based on expression of V-ATPase mRNA from a TCGA data set. In vitro, EOC cell lines were treated with chemotherapeutic agents with or without V-ATPase siRNA or PPI (omeprazole) pretreatment. Cell survival and apoptosis was assessed using MTT assay and ELISA, respectively. In vivo experiments were performed to confirm the synergistic effect with omeprazole and paclitaxel on tumor growth in orthotopic and patient-derived xenograft (PDX) mouse models. Expression of V-ATPase protein in ovarian cancer tissues was observed in 44 patients (44/59, 74.6%). Higher expression of V-ATPase mRNA was associated with poorer overall survival in TCGA data. Inhibition of V-ATPase by siRNA or omeprazole significantly increased cytotoxicity or apoptosis to paclitaxel in chemoresistant (HeyA8-MDR, SKOV3-TR) and clear cell carcinoma cells (ES-2, RMG-1), but not in chemosensitive cells (HeyA8, SKOV3ip1). Moreover, the combination of omeprazole and paclitaxel significantly decreased the total tumor weight compared with paclitaxel alone in a chemoresistant EOC animal model and a PDX model of clear cell carcinoma. However, this finding was not observed in chemosensitive EOC animal models. These results show that omeprazole pretreatment can increase the effect of chemotherapeutic agents in chemoresistant EOC and clear cell carcinoma via reduction of the acidic tumor microenvironment.

Keywords: V-ATPase; clear cell carcinoma; epithelial ovarian cancer; microenvironment; omeprazole.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Animals
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology*
  • Blotting, Western
  • Carcinoma, Ovarian Epithelial
  • Drug Resistance, Neoplasm / drug effects*
  • Drug Resistance, Neoplasm / physiology
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Gene Knockdown Techniques
  • Humans
  • Immunohistochemistry
  • In Situ Nick-End Labeling
  • Kaplan-Meier Estimate
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Neoplasms, Glandular and Epithelial / mortality
  • Neoplasms, Glandular and Epithelial / pathology*
  • Omeprazole / pharmacology
  • Ovarian Neoplasms / mortality
  • Ovarian Neoplasms / pathology*
  • Paclitaxel / pharmacology
  • Proton Pump Inhibitors / administration & dosage*
  • RNA, Small Interfering
  • Transfection
  • Vacuolar Proton-Translocating ATPases / antagonists & inhibitors*
  • Xenograft Model Antitumor Assays


  • Proton Pump Inhibitors
  • RNA, Small Interfering
  • Vacuolar Proton-Translocating ATPases
  • Omeprazole
  • Paclitaxel